Purepac to become Faulding through subsidiary consolidations.
Executive Summary
PUREPAC TO MERGE WITH FAULDING U.S. SUBSIDIARIES, CHANGE NAME to Faulding, Inc. in a series of transactions announced Aug. 10. Generic drug maker Purepac, which is 64%-owned by the Australian manufacturer Faulding, has agreed to acquire: Faulding Pharmaceuticals, which is Faulding's U.S. injectables marketing arm; Faulding Medical Devices, which is developing shell glass vial and device technologies; and Faulding Puerto Rico, which owns products and manufacturing facilities in Puerto Rico that formerly belonged to DuPont Merck.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth